Cell-free nanoparticle vaccines for customizable canine immunization

Overview

Multispec Bio presents an innovative nanoparticle-based subunit vaccine platform designed for rapid deployment in canine populations. This cutting-edge technology leverages cell-free protein synthesis to create customizable vaccines targeting multiple serotypes. By conjugating subunit vaccines onto nanoparticles, this platform enhances immunogenicity and allows for the development of virus-like-particle vaccines. The system offers flexibility to adapt antigens by merely altering the DNA template, facilitating the production of vaccines against diverse serotypes and enabling multiplex vaccination in a single application. The platform's ability to store vaccine components at room temperature until final manufacturing at the point-of-use makes it ideal for various deployment scenarios, including challenging environments like drinking water or feed.

Technical specifications

• Cell-free protein synthesis: Enables rapid customization of antigens by changing DNA templates.
• Nanoparticle conjugation technology: Enhances immunogenicity by presenting antigens on a nanoparticle surface.
• Room temperature storage: Vaccine components can be stored and later manufactured at the point-of-use.
• Multiplex capability: Allows for combining multiple serotypes in a single vaccination platform.
• Stable in complex environments: Engineered nanoparticles remain stable in environments such as water or feed.

Technology readiness level

The technology is currently at TRL 3, indicating experimental proof of concept. The next steps involve expressing and screening various leptospira antigens on nanoparticles, followed by mouse immunization studies to identify a lead candidate. Further validation includes scaling up manufacturing and conducting safety and toxicity studies in canine models.